AOD-9604 research guide for 13. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
The research peptide community in 13 connects to global networks focused on compounds like AOD-9604 — researchers in 13 draw on collective intelligence about vendor quality that applies regardless of location. The quality standards for AOD-9604 remain the same across all of 13 — a COA showing ≥98% HPLC purity, mass spectrometry identity confirmation, and acceptable endotoxin levels describes good product wherever in 13 it is purchased. 13's position in the research peptide supply chain is a destination for internationally supplied research peptides served by international vendors — the quality and handling requirements are no different from anywhere else in the world. Use this guide to evaluate AOD-9604 vendors with 13 context — the analytical standards outlined below applies throughout 13 and globally.
What Research Shows About AOD-9604
The oral bioavailability of MK-677 (Ibutamoren) distinguishes it from other compounds in the GHS class and has research design implications for 13 researchers. As an oral GHS, MK-677 avoids the technical requirements of injectable administration, making it more accessible for longer-term studies in non-specialized settings. Its half-life of approximately 24 hours produces a sustained GH elevation pattern, different from the acute pulsatile stimulation of injectable GHRPs. 13 researchers selecting between AOD-9604 options should consider whether acute pulsatile GH stimulation or sustained GH elevation is more relevant to their specific research question.
Sourcing AOD-9604 in 13 follows the standard global evaluation process, with one additional dimension: vendor experience shipping to 13. Payment and payment accessibility may also differ for 13 researchers — vendors that support several payment methods including methods available in 13 reduce friction in the ordering process. Online payment security and vendor accountability are connected — vendors who accept credit cards and provide normal consumer protections are taking on more obligation than suppliers who only accept wire transfer or digital currency. Avoid starting time-sensitive research protocols without sufficient product already in storage given the shipping variability inherent to international orders.
AOD-9604 Research Safety in 13
AOD-9604 is a research compound not licensed for human application — storage: lyophilised at −20°C, reconstituted solution stored at 2-8°C and used within 30 days of reconstitution with bacteriostatic water. Sterile reconstitution means: septum cleaned with prep pad, new needle for each draw, sterile work area — throw away reconstituted AOD-9604 that looks cloudy or has visible particles. AOD-9604 research in 13 follows the universal safety framework applied worldwide — no regional exceptions to core COA, temperature, or reconstitution protocols apply.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.